Nektar Therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. Nektar also partners with the top biopharmaceutical companies to bring new products to market. To date, Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.

News
May 3, 2016 Nektar Therapeutics Reports Financial Results for the First Quarter of 2016 »
Apr 28, 2016 Nektar to Announce Financial Results for the First Quarter 2016 on Tuesday, May 3, 2016, After Close of U.S.-Based Financial Markets »
Apr 18, 2016 Preclinical Data Presented at AACR Demonstrate that Combining NKTR-214 with Checkpoint Blockade is Superior to Dual Checkpoint Inhibition in Increasing Clonality of the T Cell Receptor (TCR) Repertoire and T Cell Tumor Infiltration »
Apr 4, 2016 Baxalta Expands Global Reach of ADYNOVATE for Hemophilia A Patients with Approval in Japan »
Contact Nektar Investor Relations
Jennifer Ruddock
Vice President of Investor Relations and Corporate Affairs
415-482-5585

Jodi Sievers
Associate Director, Investor & Corporate Communications
415-482-5593

Contact
Transfer Agent and Stockholder Services
Computershare Shareholder Services
P.O. Box 43006
Providence, RI 02940-3006
(877)290-2261
(201)680-6578
www.computershare.com/investor
 
 
Site Map Privacy Terms of Use Trademarks Site Users Guide